Combination Therapy for Treatment of Liver Disease
Granted: September 19, 2024
Application Number:
20240307502
The present disclosure relates to a method of treating non-alcoholic steatohepatitis (NASH) comprising administering to a subject with NASH a combination therapy comprising semaglutide, firsocostat, and/or cilofexor.
METHODS OF TREATING NASH
Granted: February 29, 2024
Application Number:
20240066016
The present disclosure relates generally to methods of using modulators of COT (cancer Osaka thyroid) for treating, stabilizing, or lessening the severity or progression of liver disease, in particular, Nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
Antiviral Pyrazolopiridinone Compounds
Granted: November 16, 2023
Application Number:
20230365511
The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF
Granted: August 3, 2023
Application Number:
20230242508
The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zink Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
GLP-1R MODULATING COMPOUNDS
Granted: March 30, 2023
Application Number:
20230102927
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
CAPSID INHIBITORS FOR THE TREATMENT OF HIV
Granted: February 9, 2023
Application Number:
20230038823
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
CAPSID INHIBITORS FOR THE TREATMENT OF HIV
Granted: February 9, 2023
Application Number:
20230038823
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
Combination Therapy for Treatment of Liver Disease
Granted: February 17, 2022
Application Number:
20220047678
The present disclosure relates to a method of treating non-alcoholic steatohepatitis (NASH) comprising administering to a subject with NASH a combination therapy comprising semaglutide, firsocostat, and/or cilofexor.
PD-1/PD-L1 INHIBITORS
Granted: October 21, 2021
Application Number:
20210323922
Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
CAPSID INHIBITORS FOR THE PREVENTION OF HIV
Granted: June 24, 2021
Application Number:
20210188815
The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
PD-1/PD-L1 INHIBITORS
Granted: February 25, 2021
Application Number:
20210053946
Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR
Granted: November 5, 2020
Application Number:
20200345738
The present disclosure provides crystalline forms, solvates and hydrates of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol, and methods of making.
ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE
Granted: July 16, 2020
Application Number:
20200223907
Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES
Granted: February 13, 2020
Application Number:
20200048261
A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
CAPSID INHIBITORS FOR THE TREATMENT OF HIV
Granted: February 6, 2020
Application Number:
20200038389
The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
ANTI-HIV COMPOUNDS
Granted: January 30, 2020
Application Number:
20200030327
The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.
ANTIBODIES AND FRAGMENTS THEREOF THAT BIND HEPATITIS B VIRUS PROTEIN X
Granted: October 10, 2019
Application Number:
20190309052
Provided herein are, inter alia, antibodies, antigen-binding antibody fragments, cells, polynucleotides, compositions, kits, and methods relating to the detection of HBV protein X (HBx), e.g., in vitro and in vivo. Included are antibodies and fragments thereof that bind HBx, as well as kits, cells, and compositions comprising such antibodies and fragments.
FXR (NR1H4) Modulating Compounds
Granted: October 10, 2019
Application Number:
20190308962
The present disclosure relates generally to compounds (I) which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
COT MODULATORS AND METHODS OF USE THEREOF
Granted: August 15, 2019
Application Number:
20190248807
The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
HIV PROTEASE INHIBITORS
Granted: July 11, 2019
Application Number:
20190210978
The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herin. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
